The present technology is directed to mechanical circulatory support devices and, in particular, to blood pump assemblies and associated devices, systems and methods.
The prevalence of heart failure (HF) is increasing worldwide and is an expensive burden on health care providers. Despite advances in medical care, prognosis with HF remains poor, especially in advanced stages. Heart transplantation remains limited by the supply of donor organs. The use of left ventricular assist devices (LVAD) is stagnant at approximately 5,000 implants per year due to, among other things, the need for major operative intervention and the use of cardiopulmonary bypass (CPB). Additionally, the high cost of these devices has prevented adoption in large potential markets, with some countries deciding not to fund the use of chronic LVADs.
Globally, the most common assist device for acute heart failure is the intra-aortic balloon pump (IABP), which is used clinically for limited time periods of several hours to several days. An IABP (also referred to herein as a “blood pump,” a “balloon” or an “expandable member”) is part of an IABP assembly which includes a driveline with two ends. One end is coupleable to the IABP and the other end is, often indirectly, coupleable to an external drive unit. The drive unit is the source of the working fluid (e.g., ambient air or helium), which is carried via the driveline to the IABP for inflation. The drive unit is also responsible for the deflation of the working fluid from the IABP, again via the driveline. Each year more than 150,000 patients worldwide receive IABP therapy. IABPs are much simpler than current LVADs, and the therapeutic effectiveness of counterpulsation therapy is well established. Counterpulsation requires no direct cannulation of the heart leading to easier implantation and explantation. Counterpulsation therapy is also less expensive compared to LVAD therapy.
Counterpulsation therapy is achieved by rapidly inflating the balloon immediately after aortic valve closure (dicrotic notch) and rapidly deflating the balloon just before the onset of systole. The dicrotic notch may be detected using a pressure sensor disposed at the tip of the IABP and the onset of systole may be detected using an electrocardiogram (ECG). Inflation and deflation, however, may both be triggered by either pressure sensor or ECG data. The rapid inflation of the balloon increases the diastolic aortic pressure by 20-70%, improving end-organ and coronary perfusion. The rapid deflation of the balloon reduces the ejection pressure of the native ventricle, reducing afterload and left ventricular external work. Counterpulsation therapy has been shown to be most effective in patients when their systolic aortic pressures are between 40-70 mmHg, native heart rates between 80-110 bpm, and when the counterpulsation volume (i.e., balloon volume) equals the stroke volume of the native left ventricle.
IABPs have been used in HF patients awaiting transplant and in patients undergoing coronary artery bypass surgery. The balloon is generally implanted in the descending aorta with the driveline extending through the femoral artery. This implantation being sometimes referred to herein as the “femoral implantation” and the process resulting in the femoral implantation being sometimes referred to herein as the “femoral technique.” The femoral technique is a simple one as there are no significant arterial tortuosity or arterial curvature for the implanting clinician to deal with. However, IABPs implanted via the femoral technique require the patient to remain supine for the duration of therapy with the leg immobilized because (1) changes in orientation have been shown to diminish the effectiveness of therapy, (2) ambulation may cause the balloon or balloon driveline to kink due to movement of the leg leading to cyclic fatigue and ultimately failure of the balloon assembly, and (3) ambulation increases the risk of bleeding at the arterial access in the femoral artery. Consequently, patients cannot walk, or benefit from the IABP as an extended therapy for myocardial support. The lack of ambulation has been demonstrated to lead to poorer outcomes and prolong patient recovery and hospitalization. In addition to arterial access, biocompatibility, and durability issues limit the application of IABP to short durations (typically 2-4 days). While IABP support has been used for prolonged periods, the frequency of vascular complications, infections and bleeding are high.
More recently, IABPs have been implanted in the descending aorta with the driveline extending through the axillary or subclavian artery. This implantation being sometimes referred to herein as the “axillary implantation” and the process resulting in the axillary implantation being sometimes referred to herein as the “axillary technique.” When the IABP is implanted using the axillary technique, certain mobility issues related to femoral implantation are mitigated, facilitating patient ambulation. However, with axillary implantation, the natural buoyancy of the balloon when inflated can cause the balloon to flex and the balloon may undergo cyclic fatigue and fail. Axillary implantation has typically been performed surgically via entering the chest and cutting down to the axillary/subclavian artery.
Applicant/Assignee NuPulseCV, Inc. of Raleigh, North Carolina has developed a percutaneously-delivered intravascular ventricular assist system (PiVAS) that functions as a chronic counterpulsation device as generally described in U.S. patent application Ser. No. 16/876,110, the contents of which are incorporated herein by reference in its entirety. The PiVAS includes an expandable member that is implanted in the descending aorta via an improved axillary technique using minimally invasive surgical techniques. When implanted, the driveline of the PiVAS extends through the axillary or subclavian artery. The PiVAS offers an alternative therapy for HF patients by providing partial circulatory support that may be implanted minimally invasively without entering the chest and does not require cardiopulmonary bypass (CPB) or blood products.
In one embodiment, the PiVAS includes a pneumatically driven expandable member that is designed for long-term biocompatibility and safety. The proximal end of the expandable member may be coupled to a distal end of a driveline. In one embodiment, the proximal end of the expandable member may include an engagement region that is sized and shaped to fit over a distal end of the driveline. An attachment feature such as a compression ring or other suitable element providing an airtight connection/pneumatic seal between the engagement region and driveline may be used to couple the expandable member to the driveline. The proximal end of a driveline may be coupled to a drive unit (e.g., an external driver).
The IABP employed in the PiVAS may be composed of a biocompatible, non-thrombogenic elastomeric material (e.g., Biospan®-S) or other suitable materials and may have features described in U.S. Pat. No. 8,066,628, the disclosure of which is incorporated hereby by reference in its entirety. In some embodiments, the maximum device displacement volume may be closely matched to the stroke volume of the heart and is a parameter that may be varied to provide effective counterpulsation therapy. The expandable member may have a displacement volume between about 20 ml and about 60 ml. In some embodiments, the displacement volume is about 50 ml. The IABP may have a length between about 15 cm and about 30 cm.
The expandable member may be implanted via the femoral artery and explanted via the axillary/subclavian artery without the need to enter the chest. Regarding insertion, it may be desirable to use an introducer sheath at both the femoral and axillary/subclavian arteries. An elongated delivery dilator may be disposed in the vasculature between the two introducer sheathes (e.g., by establishing a guidewire rail and then advancing the elongated delivery dilator over the guidewire and subsequently removing the guidewire). The expandable member may be introduced into the femoral artery at the associated introducer sheath. In particular, the distal end of the elongated delivery dilator may be removably coupled to a proximal end of the driveline and the proximal end of the elongated delivery dilator may be pulled to move the expandable member into position. The elongated delivery dilator may be externalized from the axillary/subclavian artery and disconnected from the proximal end of the driveline, which may be also externalized. During introduction of the expandable member into the introducer sheath at the femoral artery, the expandable member may be folded or rolled prior to insertion. A delivery sheath (e.g., a funnel or folding tube) may be utilized to reduce a dimension of the expandable member prior to insertion. The blood pump may be non-obstructive and may lay at least substantially flat in the descending aorta without folds or crevices when deflated. This enables the device to be turned off for prolonged periods. Patients may routinely stop the device for 60-plus minutes with no adverse consequences. The blood pump has been demonstrated to have a durability for over 2.5 years of use.
The driveline may be a thin (e.g., 4.2 mm outer diameter) driveline that shuttles a working fluid (e.g., air, gas, etc.) between the blood pump and the drive unit. The driveline may include an inner driveline and an outer driveline. The inner driveline may be an elongated support structure having a lumen extending there through for delivering working fluid to and from the expandable member. The inner driveline may be positioned at least partially within the patient's vasculature (e.g., between the aorta and the axillary/subclavian artery). After implantation, the inner driveline may have a distal end portion coupled to the expandable member and positioned within the patient's vasculature (e.g., the descending aorta) and a proximal end portion coupled to a distal end of the outer driveline and positioned external to the patient's vasculature at an arteriotomy in, for example, the axillary/subclavian artery, or other suitable blood vessel. The proximal end portion of the inner driveline may be coupled to a distal end of the outer driveline using any suitable technique (e.g., compression rings, suturing, gluing, stitching, etc.). An arterial interface device or stopper device (“AID”) may be used to provide hemostasis at an arteriotomy where the inner driveline exists the vasculature. The AID may enable long-term implant using minimally invasive surgical techniques. The AID may include one or more anchoring elements used to secure the device in a desired orientation or position, and one or more ports. For example, one port might provide wire axis to the patient's vasculature. The AID may have features similar to those described in U.S. Pat. No. 7,892,162, the disclosure of which is incorporated herein by reference in its entirety. The AID may be deployed or advanced over the inner driveline (e.g., that portion that is externalized from the vasculature) through a shaft in the AID that defines a lumen. The inner driveline may be inserted into and extend through the shaft. The outer driveline may be coupled to the inner driveline at a position proximate the AID.
The outer driveline may also be an elongated support structure having a lumen extending there through. The outer driveline may be positioned at least partially subcutaneously but external to the patient's vasculature. After implantation, the proximal end portion of the outer driveline may be coupled to a skin interface device (described below). The lumen of the driveline (e.g., inner and outer drivelines) may be coupled to the lumen of the expandable member to transport the working fluid to and from the expandable member. The relatively small diameter of the driveline compared to the relatively large axillary/subclavian artery mitigates risk of limb ischemia.
The drive unit may be a small, portable device that actuates the balloon pump by generating a flow of working fluid (e.g., a gas or other fluid such as ambient air or helium) into and out of the expandable member via the driveline. For example, the drive unit may generate a positive pressure to accelerate the working fluid into the expandable member, thereby inflating the expandable member and may induce a negative pressure to withdraw the working fluid from the expandable member, thereby deflating expandable member. The drive unit may utilize a bellows, a blower, a compressor, an accelerator, or other similar features to direct the flow of working fluid into and out of the expandable member. The drive unit may have a feature to prevent over-inflation of the balloon.
The skin interface device (“SID”) may be a transcutaneous device that enables the drive unit to drive operation of the expandable member. The SID may provide a stable and/or secure exit site for the driveline (e.g., the outer driveline). In an embodiment where the driveline comprises an inner driveline and outer driveline, the proximal end of the outer driveline may be coupled to an internal facing portion of SID and the drive unit may be coupled to an external facing portion of the SID. As such, SID may direct gases received from the drive unit to the outer driveline for delivery to the expandable member. The SID may be similar to the interface devices described in U.S. Pat. No. 10,137,230, the disclosure of which is incorporated herein by reference in its entirety.
The IABP may be triggered, at least in part, by pressure sensor data (e.g., from a pressure sensor element located at the distal tip of the IABP) and/or the patient's ECG via surface ECG sensors. The associated ECG sensors may be coupled to the SID via ECG leads, which relay the measurements received from the sensors to the drive unit via a wired or wireless connection. In other embodiments, the ECG sensors may be wirelessly connected to the drive unit and may transmit the sensed measurements directly to the drive unit without using the SID. The ECG sensors may be implanted, external or both implanted and external. For example, the ECG sensors may be implanted bipolar electrodes positioned at and/or proximate the heart or other appropriate tissue to determine, for example, when the left ventricle is contracting or relaxing. Counterpulsation therapy may be achieved by rapidly inflating the balloon in the aorta immediately after aortic valve closure (dicrotic notch) and rapidly deflating the balloon just before the onset of systole using a drive unit. The dicrotic notch may be sensed by the pressure sensor, and the onset of systole may be predicted or sensed using the ECG signals.
The rapid inflation of the balloon may increase the diastolic aortic pressure, improving end-organ perfusion and coronary perfusion. The rapid deflation of the balloon reduces the ejection pressure of the native ventricle, reducing afterload and left ventricular external work. This embodiment of the PiVAS provides counterpulsation therapy in patients that is more effective than a 40-ml IABP device due to a larger displacement volume. The PiVAS has enhanced durability, has a reduced or eliminated risk of being thrombogenic and/or obstructive, and is overall a low-cost, and less invasive device implant/explant procedure without the need to enter the chest. The PiVAS also has low serious adverse event (AE) burden, and enables non-obligatory support to a less-sick heart failure population (the device may be ‘on or off’ as needed).
Whether a femoral technique or an axillary technique (e.g., surgical or PiVAS) is used, it is often desirable to reduce the thickness of the IABP while retaining a desired displacement volume (e.g., 50 ml). As balloon thickness is decreased, the IABP may be more readily disposed into the applicable artery (e.g., with respect to PiVAS, through an introducer sheath or delivery sheath), and injury to blood vessel is minimized due to a smaller arteriotomy. Further, at least with balloons manufactured via blow molding, balloon thickness may be at least in part dictated by manufacturing requirements. In particular, such an IABP may lack the structural integrity to remain “vertical” within the descending aorta and prone to kinking, and further prone to roll or fold onto itself (e.g., along either or both of its longitudinal and transverse axes or at one or more angles with respect to either or both axes) or otherwise develop crevices throughout, especially when the balloon is partially deflated during counterpulsation or when the system providing counterpulsation is turned off. The balloon may also kink cyclically, or flip due to the buoyancy when the balloon is inflated in the blood, reducing the durability of the balloon and increasing the likelihood of balloon failure. Balloon failure may also lead to the leaking of air/helium into the blood stream which may cause a stroke, death, or end organ ischemia. Furthermore, balloon failure necessitates the removal and exchange of the balloon which increases cost, procedural risks including vascular injury, bleeding, and mortality. And when an IABP rolls or folds upon itself or otherwise develops crevices when disposed in the descending aorta when fully or inflated, the IABP may become obstructive, which may increase cardiac workload leading to increased heart failure or death and may require an emergency surgical procedure to remove the balloon.
Accordingly, there exists a need to prevent IABPs from rolling or folding upon themselves (or otherwise developing crevices) when disposed in a descending aorta.
Many aspects of the present technology may be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, and instead emphasis is placed on illustrating clearly the principles of the present disclosure.
NuPulseCV has developed: (1) an IABP assembly with one or more sensors (the “Sensor Technology”), generally described in a U.S. patent application filed on the same date as the present disclosure, entitled “Intra-Aortic Balloon Pump Assembly with Pressure Sensor,” identifying Joshua Ryan Woolley, Sonna Manubhai Patel-Raman, Guruprasad Anapathur Giridharan as inventors, and having attorney-docket number 8018US00/236533-30034; and (2) an intra-aortic balloon pump assembly with a balloon configured for greater support, improved reinforcements, new markers, and other improvements (the “Improved Balloon Pump Assembly Technology”), generally described in a U.S. patent application filed on the same date as the present disclosure, entitled “Intra-Aortic Balloon Pump Assembly,” identifying Joshua Ryan Woolley, Robert Christopher Hall, Duane Sidney Pinto, and Guruprasad Anapathur Giridharan as inventors, and having attorney-docket number 8019.US00/236533-30037, the contents of both applications are incorporated by reference herein in their entirety. The Sensor Technology solves certain problems associated with, among other things, axillary implantation of a IABP assembly using a pressure sensor disposed at the tip (or distal end) of the IABP, and the Improved Balloon Pump Assembly Technology solves certain problems associated with, among other things, the design of current IABPs and their drivelines. As described in the above-disclosed and incorporated U.S. patent application directed to Improved Balloon Pump Assembly Technology, it may be desirable for a balloon to have a wall thickness of between approximately 0.025-0.035 inches (0.635-0.889 mm), between approximately 0.010-0.014 inches (0.254-0.356 mm) between approximately 0.003-0.012 inches (0.076-0.305 mm) or between approximately 0.003-0.016 inches (0.076-0.406 mm). While an IABP with a wall thickness of between approximately 0.025-0.035 inches, 0.010-0.014 inches, 0.003-0.012 inches, or 0.003-0.016 inches may facilitate entry into the femoral or axillary/subclavian arteries, such an IABP with relatively thin walls render it susceptible to a lack of structural integrity. As explained herein, the present disclosure solves various problems associated with using thin-walled IABPs for mechanical circulatory support devices (e.g., counterpulsation).
Specific details of several embodiments of the present technology are described herein with reference to
Structure 200 may be made of wire or any wire-like material. The exemplary support structure 200 is configured in the shape of a loop having an open portion 210 disposed at the proximal end of the tail region 204. In one embodiment, the tail region 204 has two stem ends 212 and the head region 202 is a contiguous open-ended loop with two proximal ends. In one embodiment, the stem ends 212 are substantially parallel. Substantially parallel may mean that each stem end 212 does not deviate more than 10 degrees from a longitudinal axis of the exemplary support structure 200. Each distal end of the stem ends 212 is contiguous with a respective proximal end of the contiguous head region 202, and the proximal ends of the stems ends 212 are open defining open portion 210. In one embodiment, the proximal ends of the stem ends 212 flare outward and form flanges 214. In one embodiment the flanges 214 are substantially aligned with the transverse axis of the support structure 200. In this embodiment, substantially aligned means within 10 degrees of the reference transvers axis. In other embodiment, the flanges are not substantially aligned with the transverse axis. In one embodiment flanges 214 are flared at an angle with respect to the transverse axis. In one embodiment, the shape of the loop may be dagger-shaped. In another embodiment, the shape of the loop may substantially conform to the shape of a balloon associated with the blood pump assembly into which it is designed to be disposed within. A shape substantially conforms to the shape of the balloon means that the angles or curvatures deviate less than 10% of values of such angles and/or curvature associated with the inside walls of the balloon. Other shapes may be utilized.
Nipple 206 may be formed by tapering opposing sides of the loop-shaped head region. The opposing sides of head region may be touchingly adjacent at base 208 or not touching adjacent at base 208. The latter is depicted in
Head region 202 may be comprised of a material that is the same or different than tail region 204. Head region 202 and tail region 204 may comprise a material that exhibits elasticity or superelasticity or a material that exhibits shape memory (also known as pseudoelasticity). Elastic and superelastic materials may have a resting state and a loaded state. When in an initial resting state, the material may take on a shape that is determined during manufacture. An elastic or superelastic material may transition to a loaded state in the presence of an applied mechanical load that is equal to or greater than a threshold amount. If an applied mechanical load does not equal or is not greater than the threshold amount, the material will remain in its resting state. For so long as a mechanical load is applied that equals or is greater than a threshold amount, the elastic or superelastic material may be in a loaded state and may take on one or more different shapes based on the extent of the mechanical loading. That is, the shape of the material in the presence of a first mechanical load may be different than the shape of the material in the presence of a second mechanical loading. When in a loaded state, the structure 200 can be said to be deformed and have a deformed shape.
If all applied mechanical loads are removed or if the then-applied mechanical loads are not at least as great as the threshold amount, the material will transition to a resting state. The shape of the resting state after transition from a loaded state will be the same as determined during manufacture provided that the previously applied mechanical load does not exceed a material-specific load amount that causes nominal permanent deformation of the material (the “nominal deformation load amount”). If the previously applied mechanical load exceeds the material's nominal deformation load amount but does not exceed a material-specific load amount that causes significant permanent deformation (the “significant deformation load amount”), then the material in its subsequent resting shape will return to a shape that substantially conforms to the shape determined during manufacture. A shape substantially conforms to its shape determined during manufacture when angles or curvatures deviate less than 10% of values of such angles and/or curvature established during manufacture. If the previously applied mechanical load exceeds the significant deformation load amount, then the material in its subsequent resting shape will either retain the shape during the loaded state (i.e., it will not take on a new shape) or it will return to a shape that does not substantially conform to the shape determined during manufacture (i.e., the value of angles and curvatures may vary by more than 10% as compared to values of such angles and/or curvatures established during manufacture).
An elastic material is different from a superelastic material in that its nominal deformation load amount and its significant deformation load amount may be less that the corresponding amounts associated with a superelastic material. An example of a material that exhibits elasticity is stainless steel. An example of a material that exhibits superelasticity is Nitinol, provided that the Nitinol is not at a temperature below its memory transfer temperature (as described below).
Shape memory materials may also have a resting state and a loaded state. When in an initial resting state, the material may take on a shape that is determined during manufacture. A shape memory material may transition to a loaded state when cooled to a temperature within a material-specific deformation temperature range (e.g., 0-4 degrees C. for some compositions of Nitinol) and while such shape memory material remains at the deformation temperature range, a mechanical load is applied that is equal to or greater than a threshold amount. If an applied mechanical load is not equal to or is not greater than the threshold amount, the material remains in its resting state at least in respect of its shape. But if an applied mechanical load is at or exceeds the threshold amount when the temperature of the shape memory material is within the deformation temperature range, then the applied load will cause the shape memory material to take on one or more different shapes (i.e., be deformed) based on the extent of the mechanical load. That is, the shape of the shape memory material in the presence of a first mechanical load may be different than the shape of the material in the presence of a second mechanical load, in each instance for so long as the shape memory material is within the deformation temperature range. When in a loaded state, the structure 200 can be said to be deformed with a deformed shape.
As the temperature of the shape memory material exceeds the deformation temperature range but remains below the material-specific memory transfer temperature range (or the lowest temperature within that range), the shape memory material will retain the deformed shape caused by the applied mechanical load when the shape memory material was within the deformation temperature range. That is, the shape memory material will remain in a loaded state. However, as the shape memory material is heated to a temperature that is at or exceeds its memory transfer temperature range (e.g., 30-34 C for Nitinol), the shape memory material will transition to a resting state and to the shape as determined during manufacture, provided, that the previously applied mechanical load during deformation does not exceed the material-specific nominal deformation load amount. If the previously applied mechanical loading during deformation exceeded the nominal deformation load amount but does not exceed the shape memory material's significant deformation load amount, then the shape memory material in its subsequent resting state will return to a shape that substantially conforms to the shape determined during manufacture. A shape substantially conforms to its shape determined during manufacture when angles or curvatures deviate less than 10% of values of such angles and/or curvature established during manufacture. If the previously applied mechanical load during deformation exceeded the significant deformation load amount, then the material in its subsequent resting shape will either retain the deformation shape during the loaded state (i.e., it will not take on a new shape) or it will return to a shape that does not substantially conform to the shape determined during manufacture (i.e., the value of angles and curvatures may vary by more than 10% as compared to values of such angles and/or curvatures established during manufacture).
Returning to
The support structure 200 is configured to be disposed within a blood pump assembly having a balloon and driveline. A width of the deflated balloon may be greater than the interior diameter of the driveline. The head region 202 may be shaped and sized such that when in its resting state (e.g., as depicted in 2A) and with reference to a deflated balloon or a substantially deflated balloon (e.g., balloon 302, illustrated in
With reference to
Another mechanical load 310 (up and down arrows) may be applied by hand (e.g., by a medical professional) to externalized portion of tail region 204 at a location immediately external to the proximal end of driveline 304 to continue to advance support structure 200 into the blood pump assembly 300. A continued advancement force to advance support structure 200 into assembly 300 may be applied in the direction illustrated. The applied mechanical load 310 may cause at least a portion 311 of support structure 200, and in particular tail region 204, to assume a loaded shape that resembles the loaded shape illustrated in
With reference to
A lubricant which reduces friction (e.g., hydrophilic and hydrophobic lubricants like NuSil silicone lubricants, Surgilube, Viperslide etc.) may be used to facilitate advancement of the support structure 200 into the blood pump assembly 300. Balloon 302 may be partially inflated (e.g., at 50%) to facilitate advancement of the support structure 200 into the blood pump assembly 300. Once the support structure 200 is fully disposed within assembly 300, balloon 302 may be inflated and/or cyclically inflated/deflated for purposes of counterpulsation.
As described above in connection with
Although not depicted, implementation of support structure 200 into assembly 300, regardless of material type, may be facilitated by implantation of support structure 200 into a delivery sleeve (not depicted). Once inserted into a delivery sleeve, the delivery sleeve along with the support structure 200 therein may be implanted into assembly 300 and then the sleeve may be explanted, leaving support structure 200 disposed within assembly 300. A lubricant may be used on the inside and/or outside of delivery sleeve to facilitate the implant of the support structure 200 into delivery sleeve, the implant of the delivery sleeve into assembly 300 and the explant of delivery sleeve from support structure. The delivery sleeve may apply a sufficient mechanical load to retain support structure 200 in a sufficiently loaded state for implantation.
Removable cap 608 and proximal end of anti-backout port 604 may have complementary threaded surfaces (not depicted) to permit the removable coupling of cap 608 to port 604. Other means of mechanically coupling cap 608 to port 604 are contemplated such as various locks or locking mechanisms.
Connector 602 may include a clamp (not depicted) that clamps onto or locks and thereby secures the tail region 204 (e.g., at proximal end(s) of tail region 204). In an alternate embodiment, inside surface 607 of cap 608 may contain the proximal end(s) of tail region 204, thereby securing the tail region 204. In such an embodiment, the proximal end(s) of tail region do not extend past the cap 608. In one embodiment, proximal ends of tail region 204 are sized to rest on or proximate to inside surface 607 of cap 704. In an embodiment where proximal ends of tail region 204 have flanges 214, support 200 may be configured such that the flanges 214 rest on or proximate to the inside surface 607 of cap 704. By securing the tail region 204, whether through a clamping, locking, containing, or otherwise, support structure 200 itself and its component parts may be secured such that operational forces (e.g., buoyancy) do not drive support structure 200 out of assembly 300 during operation (e.g., during counterpulsation).
Connector 602 may include a pneumatic port 606 configured to provide a fluid connection with a driveline 304 lumen and the inner volume of balloon 302 (e.g., for the purposes of counterpulsation) when connector 602 is coupled to proximal end of driveline 304. In one embodiment, the proximal end of pneumatic port 606 is configured to be coupleable to the output of a drive unit (not depicted). For example, the proximal end of pneumatic port 606 may be configured as a hose barb connector (not depicted) and a tube that connects to the drive unit may be removably coupled to the hose barb connector such that gases from the drive unit may be used to inflate and deflate balloon 302.
Connectors 602, 702 are illustrated as y-connectors. However, other types of 3-way connectors (e.g., other types of 3-way connectors) may be utilized. For example, anti-backout port 604 may be the same port as pneumatic port 606. Other ports may be included in the same connector 602, 702.
An example of connector 602 being installed on proximal end of driveline 304 is depicted in
An example of connector 702 being installed on proximal end of driveline 304 is depicted in
Extraction of support structure 200 from assembly 300 after installation of connector 602, 702 may proceed in a manner substantially similar to that described in connection with
Support structure 1000 can be implanted and explanted into assembly 300 in the same manner as support structure 200 as was generally described in connection with
Radiopaque material may be disposed on support structure 200, 1000 to track the position of such structure 200, 1000 during radiological intervention (e.g., x-ray or fluoroscopy) or other imaging techniques.
In another embodiment, non-radiopaque material 1112 may be added to a location on the support structure 200, 1000, for example to a location on the tail region 204, 1004. In one example, the non-radiopaque material is disposed at a proximal end of tail region 204, 1004. The non-radiopaque material 1112 may serve as a visual marker, such that when the non-radiopaque material 1112 is aligned with a predetermined location of driveline 304 (or visible at or proximate a location external to the driveline 304) there is provided an indication that support structure 200, 1000 or the head region 202, 1002 is properly and fully inserted into balloon 302. For example, non-radiopaque material 1112 may be disposed on a location of the tail region 202, 1004 that corresponds to a proximal end of driveline 304 when support structure 200, 1000 is properly and fully inserted and deployed within balloon 302. In another example, the proximal end of driveline 304 may be trimmable at a location at or external to the axillary/subclavian artery 112 such that when the support structure 200, 1000 or the head region 202, 1002 is properly and fully inserted and deployed within balloon 302, the non-radiopaque material 1112 may be located at or proximate the trimmed location (e.g., the non-radiopaque material is aligned with the trimmer location). The non-radiopaque material 1112 may be disposed at any location on structure 200, 1000 or tail region 204, 1004.
In some embodiments, a sleeve (not depicted) may be utilized to advance support structure 1000 into the blood pump assembly 300. The process of using a sleeve is as described with respect to
To extract support structure 1000 using guidewire 1202, the inverse process may be performed. Optionally, if applicable, connector 602, 702 may be uninstalled. This may include removing cap 608 and/or releasing the tail region 1006 from clamp or lock, as is generally described with reference to
A such, guidewire 1202 may act to facilitate implantation and explantation of structure 200, 1000 into blood pump assembly 300. During implantation and explantation, the guidewire 1202 may support structure 200, 1000.
When disposed in assembly 300, support structure 200, 1000 may oppose forces acting on it in the descending aorta 110 when in operation (e.g., during counterpulsation) that might otherwise cause balloon 302 to roll or fold upon itself along the longitudinal axis of balloon, the transverse axis of balloon 302, or some angle with respect to either or both axes.
In one embodiment, all or a portion of the support structure 1500 is radiopaque. In one embodiment, radiopaque material 1508 (e.g., additional radiopaque material) is disposed on support structure 1500 (e.g., at the distal end of the tail region 1506). Radiopaque material 1508 may alternatively be disposed elsewhere along the head region 1501 and the tail region 1506. Radiopaque material 1508 may be used to align the support structure 1500 to the balloon or assembly into which it support structure 1500 is implanted (e.g., to ensure adequate insertion/to prevent over insertion of the support structure 1500). For example, corresponding radiopaque material may be disposed on balloon or the blood pump assembly and it may be desirable to align radiopaque material on support structure with corresponding radiopaque material on the balloon/assembly.
As was described in connection with
When the head region 1501 is disposed entirely in the balloon 302 (as may be determined when radiopaque markers 1608 and 1602 are aligned), the proximal end 1503 of the flexible tip portion 1502 may be curved (e.g., approximately 180 degrees) such that the flexible tip portion 1502 is curled back away from the distal end of the balloon 302 with the distal end 1505 of the flexible tip portion 1502 being disposed at a longitudinal position along the balloon 302 away from distal end of balloon 302. In this position the flexible tip portion 1502 may resemble a tail. The flexible tip portion 1502 may be flexible to insertion forces that cause it to curl as described above and in at least one embodiment sufficiently rigid to minimize or oppose forces acting on it in the descending aorta 110 when in operation (e.g., during counterpulsation) that might otherwise cause balloon 302 to roll or fold upon itself along the transverse axis of balloon 302, or some angle with respect to such transverse axis. The non-flexible body portion 1504 may resist or oppose, at least in part, forces acting on it in the descending aorta 110 when in operation (e.g., during counterpulsation) that might otherwise cause balloon 302 to roll or fold upon itself along the longitudinal axis of balloon 302, or some angle respect to such longitudinal axis.
The method may start with implanting a blood pump assembly (e.g., assembly 300) into a patient's descending aorta at block 2402 using, for example a femoral or axillary/subclavian technique. The method may proceed, at block 2404, where the balloon, e.g., balloon 302 of assembly 300 may be partially inflated. For example, balloon may be inflated to 50% of its volume. Next, a delivery sleeve may be inserted (e.g., into the blood pump assembly) at block 2406. The sleeve may be inserted into the driveline and/or into the balloon. A guidewire (e.g., guidewire 1202) may be inserted at block 2408. At block 2410, lubricant may be applied (e.g., to the sleeve and/or support structure (e.g., structures 200, 1000, 1500, and/or 1900). At block 2414, a support structure (e.g., structure 200, 1000) may be deformed (e.g., by placing it in a loaded state). The support structure (e.g., structure 200, 1000) may be threaded over the guidewire (e.g., guidewire 1202) at block 2414. In particular nipple tip 206, 1006 may be threaded over guidewire 1202.
In block 2416, the support structure (e.g., structure 200, 1000, 1500, 1900) may be implanted into the blood pump assembly (e.g., assembly 300). Block 2416 may include block 2416A, where the method includes disposing the nipple tip (e.g., nipple tip 206, 1006) proximate the distal end of balloon (e.g., balloon 302). The nipple tip may be touchingly adjacent or not touchingly adjacent to an inside distal end of balloon. By so disposing the nipple tip, the head region of structure (e.g., head region 202, 1002 of structure 200, 1000) may be disposed in balloon 302. Block 2416 may also include block 2416B where the structure is advanced into the balloon until a flexible tip is curved back to form a tail. For example, as depicted in
In one embodiment, one or more radiopaque markers (e.g., markers 1102-1110) is disposed along the support structure (e.g., support structure 200, 1000, 1500, 1900). The one or more radiopaque markers may be disposed in one or more of the following locations: at the distal end of the head region, at a midpoint of the head region, at a proximal endo of the head region, at a distal end of the tail region, at a first midpoint of the tail region, and at a second midpoint of the tail region. Block 2416 may further include implanting the support structure into the blood pump assembly until at least one of the one or more radiopaque markers are aligned with one or more corresponding radiopaque markers on the blood pump assembly.
In another embodiment, a non-radiopaque material is disposed at a location on the support structure. Block 2416 may further include implanting the support structure until the non-radiopaque material is aligned with a predetermined location of the driveline. The non-radiopaque material may be a visual marker and the predetermined location of the driveline may be the proximal end of the driveline.
The method may continue in block 2418 where the guidewire is removed. For example guidewire 21202 may be extracted from assembly 300. A delivery sleeve may be similarly removed (e.g., from assembly 300) in block 2420. And in block 2422, the tail region of support structure may be secured. For example, in structures 200, 1000 the stems 212, 1012 of tail region 204, 1004 may be secured. In structure 1500, tail region 1506 may be secured. And in structure 1900, tail region 1906 may be secured. In each case, a connector may be used to secure the applicable tail region. For example, connector 602 or connector 702 may be installed on a proximal end of the driveline 304 of assembly 300 and the tail region may be secured by clamping or containing the tail region. By securing the tail region, the structure may be prevented from backing out of assembly due to operational forces acting on the balloon and the structure disposed therein. Finally, the method may include block 2424 where counterpulsation therapy may be provided using the blood pump assembly having a blood pump support apparatus implanted therein. The blood pump support apparatus may include a support structure (e.g., structure 200, 1000, 1500, 1900) implanted within a balloon of assembly (e.g., balloon 302) and may further include a connector coupled to a driveline of assembly (e.g., driveline 304) that may secure a tail region of the support structure.
The above detailed description of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise forms disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. The various embodiments described herein may also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known support structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology.
Where the context permits, singular or plural terms may also include the plural or singular term, respectively. As used herein, the phrase “and/or” as in “A and/or B” refers to A alone, B alone, and A and B. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. Further, any ranges identified herein are intended to be inclusive of the numbers that define the range, whether expressly stated or not. The same applies to approximate ranges. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology may encompass other embodiments not expressly shown or described herein.
From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the invention. For example, although only discussed in connection with support structure 1500, each of support structures 200, 1000, 1500, and 1900 may comprise a core material (e.g., Nitinol or stainless steel) and may further comprise a wire, jacket, and/or coating that is applied as one or more layers to the core. For example, a flat or round wire may be coiled around the core or a polymer jacket with hydrophilic coating may be applied. PTFE coatings may also be applied (e.g., to minimize friction). Accordingly, the invention is not limited except as by the appended claims.
By implanting or disposing a support structure into a blood pump assembly having a balloon and driveline, the support structure opposes forces that may otherwise cause balloon to roll or fold upon itself (or otherwise develop crevices) along the balloon's longitudinal axis, or an angle with respect to such axis. In at least some embodiments, the support structure further opposes forces that would otherwise cause the balloon to roll or fold upon itself (or otherwise develop crevices) along the balloon's transverse axis, or an angle with respect to such axis. This solves a problem associated with using thin-walled IABPs for mechanical circulatory support devices (e.g., counterpulsation).